Persistent kneecap pain after conservative treatment

Months of physiotherapy, a course of anti-inflammatory injections, activity modifications — and the pain under the kneecap is still there. For many patients at this point, the natural question is whether something more targeted exists before committing to an operation.

First-line management for chondromalacia patella centres on non-surgical approaches: structured physiotherapy focusing on quadriceps and hip strengthening, hyaluronic acid viscosupplementation, ultrasound-guided corticosteroid injections, and platelet-rich plasma (PRP). These measures address symptoms and may slow early cartilage deterioration, but they do not repair structural damage to the patellar surface. When relief proves short-lived or incomplete, a focal lesion in the articular cartilage — rather than generalised inflammation — is the more likely explanation, and imaging review becomes the appropriate next step.

It is at this stage that a ChondroFiller injection may be relevant. Delivered as an outpatient, ultrasound-guided procedure, it occupies a defined position between conventional injection therapy and surgical options such as microfracture, MACI, or patellofemoral realignment. Patients who reach this crossroads are not necessarily facing theatre — but they may need something more regenerative than a standard injection. Understanding what that option involves, who it suits, and what the evidence shows is the focus of this article.

What chondromalacia patella means for kneecap cartilage

The patella sits within the trochlear groove of the femur, held in a dynamic track by the quadriceps mechanism. Its posterior surface — the side facing the joint — is lined with articular cartilage up to 7 mm thick, the thickest in the human body, reflecting the substantial compressive and shear forces it absorbs with every step, squat, and stair descent. When that cartilage begins to soften and break down, the result is chondromalacia patella: a deterioration of the organised collagen network that gives the tissue its shock-absorbing capacity.

Clinically, the severity of that deterioration is mapped using ICRS (International Cartilage Repair Society) grading. Grades I and II cover surface softening, early fibrillation, and partial-thickness fissuring — the cartilage is compromised but structurally present. Grades III and IV represent progressively deeper loss, from lesions extending down to the subchondral bone to full-thickness defects where bone is exposed. It is broadly at the Grade III–IV end of this spectrum that a scaffold-based approach enters the conversation at all; the earlier grades typically respond to conservative measures, or may simply not warrant intervention beyond monitoring.

A further distinction matters here, and it is one that imaging — MRI in the first instance, sometimes arthroscopic assessment — is needed to establish: whether cartilage loss is confined to a defined, focal area or spread more diffusely across the patellar surface. Symptoms such as anterior knee pain, crepitus, and discomfort on stairs do not reliably map to lesion severity or pattern. A patient with pronounced pain may have a small focal lesion; another with milder symptoms may have more generalised wear. That clinical picture can only be characterised accurately through imaging review, and it determines the appropriate pathway.

How a ChondroFiller injection works

Once imaging has mapped the defect, the treatment itself takes place in a clinic room rather than an operating theatre. Using real-time ultrasound guidance, the clinician positions a fine needle precisely at the site of the cartilage lesion beneath the kneecap — no incision, no general anaesthetic.

ChondroFiller arrives in a two-chamber syringe that keeps the collagen solution and a neutralising agent separate until the moment of delivery. As the two components mix at the needle tip and enter the joint, they encounter the neutral pH environment inside the knee, triggering rapid self-polymerisation. Within approximately three to five minutes, the material sets into a dimensionally stable, porous 3D hydrogel directly within the defect. Injection volume — typically between 1.0 and 2.3 ml — is determined in advance by the imaging assessment of defect size, so the quantity delivered is matched to the lesion rather than estimated.

ChondroFiller is acellular: it is a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH and contains no donor cells or foreign biologics. Its role is structural. The set scaffold functions as a physical lattice — a porous matrix that the body's own progenitor and mesenchymal stem cells can migrate into from the surrounding tissue. Over subsequent months, those recruited cells organise within the framework and begin remodelling it towards cartilage in a process called matrix-induced chondrogenesis. The treatment supports that repair process by giving the body's cells structure to work around; it does not transplant cartilage or guarantee tissue regrowth.

Suitable candidates for ChondroFiller injection

ChondroFiller injection is not the right fit for every patient with kneecap pain, and the distinction that determines candidacy is the same one imaging established in the previous section: focal versus diffuse cartilage loss.

The clearest candidates are patients with a confirmed focal Grade III or IV patellar cartilage defect — a defined area of deep damage, up to 3 cm² in size, with intact healthy cartilage at its borders. Patients whose deterioration is limited to early-grade softening (Grades I–II) typically have sufficient options in conservative and biologic care. Those with advanced, diffuse patellofemoral arthritis — widespread cartilage loss and substantially narrowed joint space — sit outside the scope of any cartilage-repair approach; a different conversation about joint management applies there.

Clinical timing matters too. The injection is most appropriately considered after physiotherapy, viscosupplementation, and other conservative measures have proved insufficient — not as an early response to anterior knee pain.

At the London Cartilage Clinic, patient selection follows a structured four-pillar framework: Preserve (protecting remaining tissue and slowing further degeneration), Repair (addressing focal cartilage damage directly), Restore (rebuilding lost tissue volume), and Reconstruct (structural or alignment correction). ChondroFiller injection sits within the Repair and Restore tiers of that framework. Box quantity — one, two, or three — depends on defect size and location; a current imaging review is what makes that determination possible, which is why suitability assessment and dosing are inseparable.

What the evidence shows and where the honest gaps are

Published cohort data from 2012 to 2023 show that over 81% of patients treated with ChondroFiller across knee cartilage defects achieve good-to-excellent results. Functional improvement — measured on the International Knee Documentation Committee (IKDC) scale — averages approximately 30 points and holds at three-year follow-up. MRI assessments using MOCART scoring consistently return values in the 70–87 range, indicating meaningful defect-filling and structural integration; arthroscopic re-evaluation shows a median ICRS cartilage grade improvement from 3 to 1. Across published series, symptom relief is estimated in the 70–85% range.

That evidence base has real limits. Published data comes predominantly from prospective cohort studies across general knee cartilage populations — not large randomised controlled trials. ChondroFiller carries CE-marking as a Class III medical device and has been used clinically in Europe for approximately two decades, but it holds no FDA approval in the United States.

There is a further, specific qualification for chondromalacia patella. Published outcome data targeting the patellofemoral joint directly are limited and largely unpublished as of mid-2026 — and that gap sits clearly separate from the broader knee evidence above. The underside of the patella loads differently from other cartilage surfaces, experiencing a combination of compressive and shear forces that vary substantially with knee flexion angle; broader knee cohort results cannot be straightforwardly mapped onto this surface. That distinction shapes how any outcome estimate should be read, and why an individualised imaging review matters before drawing conclusions about likely benefit.

UK availability, costs, and arranging an assessment

For UK patients considering next steps, here is how access currently works. ChondroFiller injection is not available on the NHS and is not reimbursed by Bupa or AXA private health insurance; it is accessed on a self-funded basis.

London Cartilage Clinic on Harley Street — led by Professor Paul Y.F. Lee — was the first UK clinic to offer ChondroFiller as an ultrasound-guided outpatient injection. Pricing is structured by box quantity, which reflects defect size and can only be determined after imaging review: one box costs £3,000, two boxes £5,500, and three boxes £8,000. Each tier is inclusive of consultation, imaging review, the ChondroFiller product, the injection, IV antibiotic cover, and a six-week follow-up appointment. Box quantity cannot meaningfully be quoted before a scan has been reviewed.

For patients whose patellofemoral wear extends beyond a focal cartilage defect — where the synovial lining is also significantly affected — a CFI+ combination approach pairs the ChondroFiller injection with an Arthrosamid injection from £5,500. The two products address different tissue layers: ChondroFiller targets the load-bearing cartilage surface, while Arthrosamid integrates into the synovial membrane. They are distinct products serving distinct roles rather than a single blended treatment, and which combination is appropriate depends on individual imaging and clinical assessment.

An initial consultation to discuss imaging and suitability can be arranged at londoncartilage.com.